Trial site
DM Clinical Research - Philadelphia
Philadelphia, Pennsylvania 19107, United StatesNot linked to an institution yet
- 2running trials
- 9closed trials
The trials here
What the 11 trials at this site are about, from their registry records.
- Phase
- Phase 24 trials
- Phase 34 trials
- Phase 1/22 trials
- Phase 11 trial
- Status
- Completed8 trials
- Recruiting2 trials
- Terminated1 trial
- Lead sponsor
- ModernaTX, Inc.5 trials
- Pfizer3 trials
- BioNTech SE1 trial
- Expedition Therapeutics, Inc1 trial
- Vaxcyte, Inc.1 trial
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49
NCT07284654· Phase 3· Vaxcyte, Inc.· Source
Completed
A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults
NCT06890416· Phase 3· Pfizer· Source
Completed
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age
NCT06864143· Phase 2· ModernaTX, Inc.· Source
Completed
A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People
NCT06821061· Phase 1/2· BioNTech SE· Source
Completed
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
NCT06602024· Phase 3· ModernaTX, Inc.· Source
Completed
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)
NCT06508320· Phase 2· ModernaTX, Inc.· Source
Completed
A Study About Modified RNA Vaccines Against Influenza in Healthy Adults
NCT06436703· Phase 1/2· Pfizer· Source
Completed
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age
NCT06060457· Phase 3· ModernaTX, Inc.· Source
Terminated
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
NCT05701800· Phase 1· ModernaTX, Inc.· Source
Report an error